iX Biopharma (SGX:42C) Scaled Net Operating Assets : 0.44 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

iX Biopharma's operating assets for the quarter that ended in Dec. 2024 was S$11.02 Mil. iX Biopharma's operating liabilities for the quarter that ended in Dec. 2024 was S$4.65 Mil. iX Biopharma's Total Assets for the quarter that ended in Jun. 2024 was S$14.62 Mil. Therefore, iX Biopharma's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.44.

iX Biopharma Scaled Net Operating Assets Historical Data

The historical data trend for iX Biopharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Scaled Net Operating Assets Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.32

0.57

0.48

0.31

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.34	0.53	0.30	0.42	0.44

Competitive Comparison of iX Biopharma's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Scaled Net Operating Assets falls into.

iX Biopharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

iX Biopharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2024 )
=	(Operating Assets (A: Jun. 2024 )	-	Operating Liabilities (A: Jun. 2024 ))	/	Total Assets (A: Jun. 2023 )
=	(12.853	-	5.083)	/	24.928
=	0.31

where

	Operating Assets		(A: Jun. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	14.624	-	1.771
=	12.853

	Operating Liabilities		(A: Jun. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	10.284	-	2.324	-	2.877
=	5.083

iX Biopharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2024 )
=	(Operating Assets (Q: Dec. 2024 )	-	Operating Liabilities (Q: Dec. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(11.017	-	4.647)	/	14.624
=	0.44

where

	Operating Assets		(Q: Dec. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	13.084	-	2.067
=	11.017

	Operating Liabilities		(Q: Dec. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	9.57	-	1.969	-	2.954
=	4.647

iX Biopharma Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines